How well does XALKORI(Crizotinib) work?

XALKORI has shown significant efficacy in clinical trials across its indicated uses.

Clinical Benefits of XALKORI

In studies, XALKORI demonstrated improved progression-free survival and high objective response rates in patients with ALK or ROS1-positive NSCLC. Among pediatric and young adult patients with ALCL, an 88% response rate was observed. For patients with IMT, response rates reached 86% in pediatric populations and included complete and partial responses in adults. The drug is taken continuously until disease progression or unacceptable toxicity occurs.